注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
PTC Therapeutics Inc是一家科學驅動的全球生物製藥公司。該公司致力於可為罕見疾病患者帶來益處的臨床差異藥物的發現、開發和商業化。該公司擁有一個投資組合管道,其中包括商業產品以及處於不同開發階段(包括臨床、臨床前以及研究和發現階段)的候選產品,專注於針對罕見疾病和腫瘤等多種治療領域的新療法的開發。該公司有兩種產品:Translarna(ataluren)和Emflaza(deflazacort),用於治療杜興型肌營養不良症(DMD)。該公司擁有一系列針對中樞神經系統(CNS)的罕見單基因疾病的基因治療產品候選產品,其中包括用於治療芳香L-氨基酸脫羧酶(AADC)的PTC-AADC和用於苯丙酮尿症(PKU)疾病的PTC923。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Michael Schmertzler | 69 | 2001 | Independent Chairman of the Board |
Alethia Rene Young | 43 | 2022 | Independent Director |
Mary L. Smith | 60 | 2021 | Independent Director |
Matthew B. Klein | 51 | 2020 | CEO & Director |
Stuart W. Peltz | 63 | 1998 | Co-Founder, Senior Consultant & Member of Scientific Advisory Board |
Allan Steven Jacobson | 77 | 1998 | Co-Founder, Chairman of Scientific Advisory Board & Independent Director |
William F. Bell | 67 | 2023 | Independent Director |
Stephanie Smith Okey | 63 | 2018 | Independent Director |
Joseph D. Puglisi | - | 2003 | Member of Scientific Advisory Board |
David P. Southwell | 63 | 2005 | Independent Director |
Jerome Bernard Zeldis | 74 | 2012 | Independent Director |
Marvin Wickens | - | - | Member of Scientific Advisory Board |
Robert J. Schneider | - | - | Member of Scientific Advisory Board |
Eric N. Jacobsen | 64 | - | Member of the Scientific Advisory Board |
Glenn Daniel Steele | 79 | 2015 | Independent Director |
Emma Reeve | 63 | 2018 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核